The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Athenex; Bluebird Bio; Bristol-Myers Squibb; Calibr; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Sana Biotechnology; Sellas Life Sciences
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Kite, a Gilead company; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - ADC Therapeutics; Gamida Cell; Genmab; Incyte; Kite/Gilead; MorphoSys; Novartis; Omeros; Puma Biotechnology (I); Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Juno/Celgene; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
Houston Holmes
Leadership - Exuma Biotech
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene/Juno; Celgene; crispr therapeutics; Epizyme; Genentech; Janssen; Karyopharm Therapeutics; Kite/Gilead; Rigel; TG Therapeutics
Speakers' Bureau - Dova Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Seagen
Research Funding - Adicet Bio (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); Caribou Biosciences (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Unum Therapeutics (Inst); Viracta Therapeutics (Inst)
 
John Hinkle
Consulting or Advisory Role - Adicet Bio
 
Jackie Kennedy-Wilde
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
 
Ori Maller
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
 
Maggie Weinstein
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
 
Francesco Galimi
Employment - Adicet Bio
Leadership - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio; Amgen
Patents, Royalties, Other Intellectual Property - Adicet Bio
 
Rose Lai
Employment - Adicet Bio
Leadership - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
Patents, Royalties, Other Intellectual Property - Adicet Bio; University of Southern California; Zymeworks
 
Don A. Stevens
No Relationships to Disclose